Formula I Compounds for Neurodegenerative Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative, myodegenerative, and lysosomal storage disorders are limited, with few effective options available for preventing or treating these conditions.
Innovation Solution
The development of compositions and methods involving compounds of Formula I, which include specific aryl or heteroaryl substituents, are administered to treat or prevent neurodegenerative, myodegenerative, and lysosomal storage disorders by inhibiting toxic protein aggregation and promoting lysosomal clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative, myodegenerative, and lysosomal storage disorders, then the existing treatment options are maintained, but the effectiveness and availability of treatments remain limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of tyrosine kinase inhibitors (changing molecular parameters such as aryl and heteroaryl substituents) to create compounds with improved therapeutic efficacy. The compounds of Formula I represent specific parameter variations of TKI molecules designed to enhance their ability to treat neurodegenerative, myodegenerative, and lysosomal storage disorders while maintaining selectivity and reducing off-target effects.
2Reliability
If new compounds of Formula I are developed to treat these disorders, then treatment effectiveness is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent applies universality by developing tyrosine kinase inhibitor compounds that can treat multiple types of disorders (neurodegenerative, myodegenerative, and lysosomal storage disorders) through a single mechanism of action. The compounds of Formula I are designed to inhibit toxic protein aggregation and promote lysosomal clearance across different disease contexts, allowing one class of compounds to address multiple therapeutic needs without requiring entirely different treatment regimens for each disorder type.
Data Source
AI summary
Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a myodegenerative disease, a prion disease or a lysosomal storage disease in a subject.